MINI ORALS 2026
Bladder & Urothelial Cancers
Abstract Code: IUC25665-89
BK Virus Associated Urothelial Carcinoma – A Regional Cohort of Kidney Transplant Recipients
Abstract Code: IUC25722-83
Bladder Cancer in Young Women: Clinicopathological Features and Risk Factors from a Multi-Center Retrospective Study
Abstract Code: IUC26529-89
Sex Differences in Enfortumab Vedotin Efficacy and NECTIN-4 Levels in Metastatic Urothelial Cancer
Abstract Code: IUC26589-95
First-Line or Maintenance Immune Checkpoint Inhibitors in Older Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis
Abstract Code: IUC26590-87
Outcomes of Novel Systemic Therapies in Advanced Upper Tract Urothelial Carcinoma: A systematic Review and Meta-Analysis
Abstract Code: IUC26600-79
‘STATE-OF-THE-NATION’ STUDY: UNDERSTANDING NHS TREATMENT PATHWAY TO ADVANCE HR NMIBC PATIENT CARE in the UK (SPAN UK)
Abstract Code: IUC26674-90
Impact of delayed radical cystectomy following neoadjuvant chemotherapy on oncological outcomes in Muscle-invasive bladder cancer
Abstract Code: IUC26692-90
Benchmarking Artificial Intelligence Based Clinical Prediction Models for Immune Checkpoint Inhibitor Response and Overall Survival in Bladder Cancer
Abstract Code: IUC26698-96
Durvalumab + BCG therapy in BCG-naïve, high-risk NMIBC: efficacy and safety analyses from POTOMAC
Prostate Cancer
Abstract Code: IUC25511-79
Prostate volume changes during longer fractionated and ultra-hypofractionated MR-guided adaptive radiotherapy leveraging the MOMENTUM registry
Abstract Code: IUC26645-88
Challenges of AI in Surgical Planning for Radical Prostatectomy: Barriers and Progress
Abstract Code: IUC26661-86
Real-world outcomes in patients with Metastatic Hormone-Sensitive Prostate Cancer treated with androgen deprivation therapy and Apalutamide - A single centre study
Abstract Code: IUC26667-92
Assessment of QRISK®3 and Major Cardiovascular Events in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with ADT ± ARPI ± Docetaxel: A Retrospective Cohort Study
Abstract Code: IUC26679-95
A pilot study of the implementation of the G8 frailty assessment in oncology clinics for patients with newly diagnosed metastatic hormone sensitive prostate cancer
Renal Cell Carcinoma
Abstract Code: IUC25517-85
First‑line TKI, ipilimumab–nivolumab, and lenvatinib–pembrolizumab in metastatic non–clear cell RCC: real‑world survival across two UK centres
Abstract Code: IUC25693-90
Real-world effectiveness of pembrolizumab plus axitinib in metastatic renal cell carcinoma in Panama
Abstract Code: IUC26559-92
Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Evidence from an Immunotherapy-Inaccessible Cohort
Abstract Code: IUC26562-86
Integrating Transcriptomic Profiles and Clinical Outcomes Across MEET-URO Risk Groups in Metastatic Renal Cell Carcinoma: A Comparative Analysis with the IMDC Framework
Abstract Code: IUC26657-91
Sex-based Disparities in Metastatic Renal Cell Carcinoma: Real-World Data from Meet-URO33 Study.
Abstract Code: IUC26658-92
Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Evaluating Ethnic Variations
Abstract Code: IUC26666-91
Prediction of immune-related adverse events (irAEs) with hematologic markers in patients receiving first-line immune checkpoint inhibitor (ICI)-based therapy in metastatic renal cell carcinoma (mRCC)
Abstract Code: IUC26671-87
Adjuvant Pembrolizumab in RCC: Real world experience in Northern Ireland 2022-2026
Abstract Code: IUC26672-88
Treatment beyond progression in primary refractory mRCC during 1L systemic therapy (Meet-Uro 33)
Abstract Code: IUC26678-94
Impact of Metastatic Patterns on First-Line Therapy in mRCC: Meet-URO 33
Abstract Code: IUC26682-89
Efficacy and tolerability of immune checkpoint inhibitors in older versus younger patients with metastatic renal cell carcinoma: a real-world Asian cohort
Abstract Code: IUC26686-93
Synergistic potential of cabozantinib and radiotherapy in advanced renal cell carcinoma by site of irradiation
Abstract Code: IUC26690-88
Cannabinoid Receptor Profiling Reveals a Low CB1 and High CB2 signature in Clear Cell Renal Cell Carcinoma
Abstract Code: IUC26693-91
CHOLESTEROL HOMEOSTASIS AND IMMUNE-INFLAMMATORY PROFILES IN PATIENTS WITH mRCC RECEIVING IMMUNOTHERAPY
Abstract Code: IUC26694-92
Stereotactic Body Radiotherapy and Immunotherapy for Metastatic Renal Cell Carcinoma Croatian Uro-Oncology Network Experience
Abstract Code: IUC26700-80
Real world analysis of first line systemic anti-cancer treatment for metastatic Renal cell carcinoma
Abstract Code: IUC25516-84
Non clear renal cell carcinoma: metastatic patterns and survival from a real-world cohort
Testicular & Rare Cancers
Abstract Code: IUC26664-89
De-escalated management of stage I seminoma: three decades of real-world outcomes
Abstract Code: IUC26687-94
Clinical and Pathologic Outcomes of Resection of Thoracic Residual Masses in Germ Cell Tumors
Prostate Cancer UK - Education
Patient Voice & Sexual Wellbeing: In conversation with Steve Allen